Randomized Phase 3 Trial of Abiraterone Acetate in Men with Metastatic Castration-Resistant Prostate Cancer and No Prior Chemotherapy

BACKGROUND: Abiraterone acetate, an androgen biosynthesis inhibitor, improves overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) post-chemotherapy. Many mCRPC patients never receive chemotherapy and thus cannot benefit from abiraterone acetate; we evaluated this agent i...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Ryan, Charles J., Smith, Matthew R., de Bono, Johann S., Molina, Arturo, Logothetis, Christopher J., de Souza, Paul, Fizazi, Karim, Mainwaring, Paul, Piulats, JM, Ng, Siobhan, Carles, Joan, Mulders, Peter F.A., Basch, Ethan, Small, Eric J., Saad, Fred, Schrijvers, Dirk, Van Poppel, Hendrik, Mukherjee, Som D., Suttmann, Henrik, Gerritsen, Winald R., Flaig, Thomas W., George, Daniel J., Yu, Evan Y., Efstathiou, Eleni, Pantuck, Allan, Winquist, Eric, Higano, Celestia S., Park, Youn, Kheoh, Thian, Griffin, Thomas, Scher, Howard I., Rathkopf, Dana E.
Format: Artigo
Jezik:Inglês
Izdano: 2012
Teme:
Article
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC3683570/
https://ncbi.nlm.nih.gov/pubmed/23228172
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1209096
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki